ATF5 and primary cutaneous T-cell non-Hodgkin lymphoma: Given the requirement for long-term medical treatment in CTCL patients, this rapid transition to subsequent therapeutic regimen indicated that patients with high ATF5 expression benefited less from current treatments, mainly due to unsatisfactory therapeutic effects (30).